<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72226">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955642</url>
  </required_header>
  <id_info>
    <org_study_id>1208094</org_study_id>
    <secondary_id>2013-000313-20</secondary_id>
    <nct_id>NCT01955642</nct_id>
  </id_info>
  <brief_title>Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke</brief_title>
  <acronym>AAPIX</acronym>
  <official_title>Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke : Role of Platelet alpha2-adrenergic Receptors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe de Recherche sur la Thrombose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <authority>France: French Data Protection Authority</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ischemic stroke (AIC) is the leading cause of non-traumatic disability in adults, the second
      leading cause of dementia and the third leading cause of death in France.

      Clopidogrel is one of the recommended first line in the secondary prevention of AIC non
      cardioembolic origin. However recurrences occur in approximately 9% of patients receiving
      clopidogrel. Some studies in patients with coronary artery disease have made ​​the
      connection between these treatment failures and non-biological response to clopidogrel. This
      non-biological response is found for approximately 30% to 50% of patients. Several
      mechanisms may explain this non-response. The most accepted mechanism is pharmacokinetic.
      Indeed, clopidogrel is a prodrug that requires intestinal absorption by P-glycoprotein (PGP)
      and a transformation by hepatic cytochrome into active metabolites. The genetic polymorphism
      of proteins involved in these two steps explain the low plasma concentration of active
      metabolites and thus the low efficacy of clopidogrel in some patients.

      A new pharmacodynamic hypothesis suggests the involvement of platelet alpha 2-adrenergic
      receptors. The activation of these receptors potentiates signaling pathway P2Y12 receptor
      (channel inhibited by clopidogrel) and helps reduce platelet aggregation inhibiting response
      to clopidogrel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interest in the biological response to clopidogrel in the AIC is innovative because few data
      are available in this area. In addition to testing a new pharmacodynamic hypothesis, we also
      wish to study and compare other measures of platelet function methods in order to be able to
      use commonly in treatment decisions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>adrenergic component of the platelet response</measure>
    <time_frame>5 days after taking clopidogrel</time_frame>
    <safety_issue>No</safety_issue>
    <description>adrenergic component of the platelet response is estimated by the difference between the maximum percentage of platelet aggregation by light transmission aggregometry (LTA) with the addition of ADP(adenosine diphosphate)  + ADP versus selective agonist (epinephrine)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VASP-CMF</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <safety_issue>No</safety_issue>
    <description>Platelet reactivity index (PRI) by VASP CMF (flow cytometry) method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ELISA VASP</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <safety_issue>No</safety_issue>
    <description>Platelet reactivity index (PRI-ELISA) using ELISA VASP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>active metabolite of clopidogrel</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <safety_issue>No</safety_issue>
    <description>Rate of residual plasma active metabolite of clopidogrel (R-130964)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of MDR-1 and P450 2C19</measure>
    <time_frame>After 5 days taking clopidogrel</time_frame>
    <safety_issue>No</safety_issue>
    <description>Genotyping of MDR-1 and P450 2C19</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Brain Ischemia</condition>
  <condition>Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>AVC</arm_group_label>
    <description>Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as usual indications</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>75 mg milligrams per days of PLAVIX</description>
    <arm_group_label>AVC</arm_group_label>
    <other_name>PLAVIX(R)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with non-cardioembolic AIC requiring initiation of treatment with clopidogrel as
        usual indications
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consent signed

          -  Patients with non-cardioembolic AIC requiring initiation of treatment with
             clopidogrel as usual indications

          -  normal standard biological tests

        Exclusion Criteria:

          -  Need to continue aspirin therapy

          -  Patients with a recurrence of clopidogrel AIC

          -  Patient already tacking clopidogrel

          -  Drugs interfering with the adrenergic system alpha blockers, alpha 2 receptor
             agonists (alpha-methyldopa) and alpha2 receptor inhibitors (Mianserin, Mirtazapine,
             yohimbine)

          -  Contra indication of clopidogrel and / or any of its excipients
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerome VARVAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerome VARVAT, MD</last_name>
    <phone>(0)477127770</phone>
    <phone_ext>+33</phone_ext>
    <email>jerome.varvat@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nora MALLOUK, PhD</last_name>
    <phone>(0)47710281</phone>
    <phone_ext>+33</phone_ext>
    <email>nora.mallouk@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jerome VARVAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre GARNIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magali EPINAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine ACCASSAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 17, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clopidogrel</keyword>
  <keyword>Brain Ischemia</keyword>
  <keyword>Ischemic attack</keyword>
  <keyword>Biological response to clopidogrel</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
